Studies analyze blue light cystoscopy, irregularities in brain activity, the origins of abnormal bone formations, and HIV transcription.

A drug that targets a protein known as phosphatidylserine boosted the response rate for hepatocellular carcinoma (HCC) patients receiving immunotherapy without compromising their safety, according to results of a phase two clinical trial conducted by UT Southwestern Medical Center.

A person’s IQ during high school is predictive of alcohol consumption later in life, according to a study by UT Southwestern Medical Center researchers published in Alcohol and Alcoholism.

A team led by researchers from UT Southwestern Medical Center and a university in South Korea has identified a subset of brain cells whose activation may be partially responsible for the effects of a popular class of weight loss drugs that includes semaglutide and tirzepatide.

A computer model developed by UT Southwestern Medical Center researchers significantly enhances the ability of scientists to detect communication between cells according to a new study published in Nature Methods.

It’s well known that the sun’s ultraviolet (UV) light can wreak havoc on the skin. But most people don’t realize some commonly used products and medications can make us more susceptible to sunburn and other adverse reactions.

A novel combination therapy slowed cognitive decline in elderly patients with a history of depression – a major risk factor for developing Alzheimer’s and other forms of dementia, a study led by UT Southwestern Medical Center’s new Chair and Professor of Psychiatry found.

– The quintessential female sex hormone estrogen stimulates cells that line blood vessels to deliver insulin to muscles, lowering blood sugar and protecting against Type 2 diabetes, UT Southwestern Medical Center researchers report.

UT Southwestern Medical Center has been selected to be one of 12 NIH Nutrition Obesity Research Centers in the nation – and the only one in Texas – to investigate the causes, prevention, and treatment options for obesity, a chronic disease affecting more than 40% of the U.S. population with medical

A weekly dose of semaglutide (Ozempic, Wegovy) significantly reduced the risk of major adverse cardiovascular events (MACEs) in people who are overweight or obese with cardiovascular disease but no diabetes regardless of blood sugar level, according to a clinical trial including researchers from UT